Latest Investment News

FINEOS Corporation Holdings plc reported a 4.2% increase in revenue to €67.1 million for H1 2025, alongside a significant 76% reduction in losses, driven by subscription growth and operational efficiencies.

Titomic Limited reported a 22.5% increase in revenue to $9.43 million for FY2025 but saw losses soar by over 67%, highlighting ongoing financial challenges despite growth.

Clever Culture Systems Ltd has reported a remarkable 288% jump in revenue to $6.63 million for the year ended June 2025, turning around from a loss to a net profit of $1.68 million, buoyed by strong product sales and government support.

betr Entertainment Limited posts a 140% turnover increase to $1.42 billion and achieves a positive EBITDA of $7.2 million in FY25, driven by strategic mergers and market exits. The company ups its takeover bid for PointsBet, signaling aggressive consolidation ambitions.

Centuria Industrial REIT has expanded its exchangeable notes offering to $325 million, reflecting robust investor appetite, while simultaneously repurchasing nearly all its existing notes due 2028.

Resimac Group Ltd delivered a robust FY25 performance, marked by strong organic growth in home loans and asset finance, bolstered by the strategic acquisition of Westpac's $1.5 billion auto portfolio. The company raised dividends to 19 cents fully franked, reflecting confidence amid rising impairment expenses.

Caravel Minerals has appointed Primero Group as the EPCM contractor for its Caravel Copper Project, with the Definitive Feasibility Study now fully funded and on track for completion in early 2026.

Dicker Data Ltd reported a robust 15.7% increase in gross revenue for H1 FY25, driven by AI deployments and accelerated PC refresh cycles. The company also provided confident FY25 guidance amid strategic moves into AI ecosystems and cybersecurity.

Australian Unity Office Fund reports a $35.6 million loss for FY25 as it advances asset disposals ahead of planned delisting, with the final property sale facing settlement uncertainty.

Clinuvel Pharmaceuticals has reported a robust financial year ending June 2025, marked by solid revenue growth and sustained profitability, while advancing its clinical pipeline and maintaining a strong balance sheet.

Clinuvel Pharmaceuticals has reported its ninth consecutive year of revenue and profit growth, driven by strong sales of SCENESSE® and strategic investment in vitiligo clinical trials. The company also declared its eighth consecutive dividend, underscoring financial resilience.

Sequoia Financial Group reported a robust FY25 with a 13.7% rise in EBITDA and a 44% jump in funds under advice, underpinned by strategic restructuring and technology investments.